Sun Pharma Subsidiary gets Health Canada’s nod for Acne Cream WINLEVI

Sun Pharmaceutical Industries’ wholly owned subsidiary — Sun Pharma Canada Inc received Health Canada’s approval for WINLEVI (clascoterone cream 1%). WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older, and the newest Health Canada-approved formulation to target the hormonal component of acne for Canadian patients in 40 years. 

WINLEVI is thought to inhibit the effects of androgen receptors in cells of the sebaceous glands (oil-producing glands in the skin) to help reduce sebum (oil) production and inflammatory cytokines and thus inhibit the androgen cascade. 

Instead of a topical approach to acne treatment that focuses on follicular hyperkeratinization, reducing inflammation or exerting antibacterial effects, WINLEVI targets the androgen receptor in the skin to tackle sebum production and inflammation. WINLEVI will be available in Canada this fall. 

Sun Pharmaceutical Industries is the world’s fourth-largest specialty generic pharmaceutical company and India’s top pharmaceutical company. The company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries have various manufacturing facilities spread across the world with trading and other incidental and related activities extending to the global market. 

On Tuesday, the stock opened at Rs 1009.85 and touched a high and low of Rs 1009.85 and Rs 989.55 respectively.  

The BSE group ‘A’ stock of face value of Rs 1 has touched a 52-week high and low of Rs 1071.90 and Rs 794.25, respectively. 

Last one week high and low of the scrip stood at Rs 1009.85 and Rs 984.50 respectively. The current market cap of the company is Rs 2,38,080.43 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.12% and 9.41% respectively.